Galectin Inhibitor GR-MD-02

Known as: GR-MD-02, Galactoarabino-rhamnogalacturonate 
A carbohydrate-based galectin inhibitor, with potential antineoplastic activity. Galectin inhibitor GR-MD-02 binds to the carbohydrate-binding domain… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
01220132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis… (More)
  • figure 1
  • figure 2
Is this relevant?
2016
2016
BACKGROUND Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without approved… (More)
Is this relevant?
2015
2015
Immunosuppression and reduced cytolytic function of tumor-infiltrating lymphocytes are major obstacles to creating effective… (More)
Is this relevant?
2013
2013
Galectin-3 protein is critical to the development of liver fibrosis because galectin-3 null mice have attenuated fibrosis after… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2013
2013
Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without effective therapy. Some data… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?